title: Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
abstract: OBJECTIVE
  To evaluate the tolerability and efficacy of oxaliplatin-based chemotherapy (OBC) in patients ≥ 75 years old with metastatic colorectal cancer (CRC).
  
  
  METHODS
  We reviewed the medical records of 126 patients with unresectable stage IV CRC in terms of OBC administered as first-line chemotherapy whenever feasible.
  
  
  RESULTS
  Use of first-line OBC was significantly less frequent in patients ≥ 75 years old (n=18) than in patients <75 years old (n=108) (46% vs. 81% p<0.01). When analysis was restricted to patients receiving OBC, the two age groups did not differ significantly in terms of response rate (44% vs. 36%, p=0.54), progression-free survival (18.7 months vs. 13.0 months, p=0.44), overall survival (25.4 months vs. 17.5 months, p=0.53), and frequency of grade 3-4 toxicity (72% vs. 58%, p=0.26).
  
  
  CONCLUSIONS
  In selected patients aged 75 years or greater, the clinical outcomes of OBC seem equivalent to those of younger patients.
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, 1981, Kamoda, Kawagoe, Saitama, 350-8550, Japan. mfukuchi@saitama-med.ac.jp.
authors.forename: Minoru
authors.initials: M
authors.lastname: Fukuchi
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Tajima
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Masaru
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Chika
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hatano
authors.forename: Takeaki
authors.initials: T
authors.lastname: Matsuzawa
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kumamoto
authors.forename: Youichi
authors.initials: Y
authors.lastname: Kumagai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Baba
authors.forename: Erito
authors.initials: E
authors.lastname: Mochiki
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D060828:Induction Chemotherapy; D000077146:Irinotecan; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D016016:Proportional Hazards Models; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: Elderly patients; metastatic colorectal cancer; oxaliplatin-based chemotherapy